Immune Therapeutics, Inc. announced the appointment of Mr. Glen Farmer, age 53, as the new Chief Financial Officer of the Company. Mr. Farmer replaces Dr. Stephen Wilson who was serving as the interim Chief Financial Officer. Dr. Wilson resigned as the interim Chief Financial Officer effective as of the same date.

Dr. Wilson's resignation as interim Chief Financial Officer was not due to any disagreement with the Company on any matter relating to its operation, policies (including accounting or financial policies) or practices. Dr. Wilson remains the Company's President and Chief Executive Officer and a Director of the Company. Mr. Farmer has over 30 years of experience creating and scaling Finance, Accounting and Operations for startup and development-stage companies.

He has held numerous senior financial roles with startups and large corporations in the private and public sectors across multiple industries. He was most recently the Vice President and U.S. Controller at iAnthus Capital Management, Inc., a public company with 1,000+ employees and 42 consolidated subsidiaries. Prior to iAnthus, he held CFO positions with Croma Pharmaceuticals, Inc. and Primetime Life Sciences and served as Controller and Principal Accounting Officer for Avalon Pharmaceuticals.

Mr. Farmer received his bachelor's degree in accounting from the University of Maryland, and his MBA with concentration in finance from Mount St. Mary's University. He joins Immune to oversee Immune's global finance team.

He will report directly to Immune's Chief Executive Officer.